Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIKFYVE | Q9Y2I7 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 6/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 3/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943014 | 0.97 | PIKFYVE (0.65) | PIKFYVEMEN1TSHRKMT2ABRAF | |
| SCHEMBL21943439 | 0.92 | PIKFYVE (0.56) | PIKFYVEMEN1TSHRKMT2ABRAF | |
| SCHEMBL21943068 | 0.89 | PIKFYVE (0.54) | PIKFYVEMEN1TSHRKMT2ABRAF | |
| SCHEMBL21943516 | 0.88 | PIKFYVE (0.75) | PIKFYVEMEN1TSHRKMT2ABRAF | |
| SCHEMBL21943016 | 0.88 | PIKFYVE (0.70) | PIKFYVEBRAFKDRMAPK14ABL1 | |
| SCHEMBL21943532 | 0.87 | PIKFYVE (0.68) | PIKFYVEMEN1TSHRKMT2ABRAF | |
| SCHEMBL21943007 | 0.86 | PIKFYVE (0.61) | PIKFYVEMEN1KMT2ABRAFKDR | |
| SCHEMBL21943735 | 0.84 | BRAF (0.51) | PIKFYVEMEN1TSHRKMT2ABRAF | |
| SCHEMBL22024706 | 0.83 | PIKFYVE (0.78) | PIKFYVEMEN1TSHRKMT2ABRAF | |
| SCHEMBL12412290 | 0.81 | MEN1 (0.71) | MEN1TSHRKMT2ABRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | XIAMEN UNIVERSITY (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP4A11, CYP2D6, CYP3A43 | PIKFYVE 2706/4885MEN1 1374/4885TSHR 3409/4885 |
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | CYP4A11, CYP2D6, CYP3A43 | PIKFYVE 2706/4885MEN1 1374/4885TSHR 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.